Galicaftor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Galicaftor Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Galicaftor can convert its Small molecule drug profile and CFTR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Galicaftor (query alias: Galicaftor) |
|---|---|
| Modality / target | Small molecule drug; CFTR; CFTR modulators |
| Highest global status | Phase 2 |
| Originator | Lakefront Biotherapeutics |
| Active developers | Sionna Therapeutics, Inc. |
The MCP disease footprint includes Cystic Fibrosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04853368 | Phase 2 | Terminated | 48 | Cohorts 1 and 2: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) |
| NCT07035990 | Phase 1 | Recruiting | 144 | To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-109 when administered in combination to healthy participants |
| NCT05538585 | Phase 1 | Completed | 24 | Maximum Observed Plasma Concentration (Cmax) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Phase 2; n=48; evaluation: not stated. Reported fields: Cohorts 1 and 2: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(Mean): LS Mean of Difference = 2.6(90% CI, 1.22 - 4.04), P-Value = 0.002; LS Mean of Difference = 1.3(90% CI, -2.07 to 4.67), P-Value = 0.254; LS Mean of Difference = 0.9(90% CI, -5.07 to 6.77), P-Value = 0.402; Cohorts 1 and 2: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(Mean): LS Mean of Difference = 2.6(90% CI, 1.22 - 4.04), P-Value = 0.002; LS Mean of Difference = 1.3(90% CI, -2.07 to 4.67), P-Value = 0.254; LS Mean of Difference = 0.9(90% CI, -5.07 to 6.77), P-Value = 0.402; Cohorts 1 and 2: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(Mean): LS Mean of Difference = 2.6(90% CI, 1.22 - 4.04), P-Value = 0.002; LS Mean of Difference = 1.3(90% CI, -2.07 to 4.67), P-Value = 0.254; LS Mean of Difference = 0.9(90% CI, -5.07 to 6.77), P-Value = 0.402
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
Phase 2; n=78; evaluation: not stated. Reported fields: -; -; -
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
Phase 2; n=59; evaluation: Negative. Reported fields: TRAE = 29.2 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Galicaftor addresses Cystic Fibrosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-07-16 | AbbVie sells cystic fibrosis compounds to Sionna Therapeutics | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination treatments for cystic fibrosis characterized by a 3849 + 10kb c-to-t CFTR mutation”. The milestone feed surfaced a patent-application signal described as “Deuterated CFTR modulators and methods of use”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
